MeiraGTx Holdings plc (MGTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

MeiraGTx Holdings plc (MGTX) closed at USD 9.41 on 2026-10-14, a change of +1.6 % over the past year, with a market capitalization of USD 949.87M.

MeiraGTx Holdings plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

MeiraGTx Holdings plc key figures

Previous close

USD 9.41 (2026-10-14)

1-year change

+1.6 %

Market cap

USD 949.87M

Enterprise value

USD 919.23M

P/E ratio (trailing)

11.37

P/E ratio (forward)

-6.49

EPS (trailing)

0.87

EPS (forward)

-1.53

PEG ratio

n/a

Price to book

4.32

Revenue growth

8,608.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.35

Employees

393

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About MeiraGTx Holdings plc

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for MeiraGTx Holdings plc and compare it with other stocks.